Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06454357
PHASE2/PHASE3

A Clinical Study of B007 in the Treatment of Pemphigus.

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.

Official title: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Pemphigus.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

132

Start Date

2024-07-12

Completion Date

2026-12-31

Last Updated

2024-10-10

Healthy Volunteers

No

Conditions

Interventions

DRUG

B007

B007:high dose/low dose: Subcutaneous injection was administered on days 1 and 15

Locations (12)

Peking University First Hospital

Beijing, China

The Second Xiangya Hospital of Central South University

Changsha, China

Chengdu Second People's Hospital

Chengdu, China

West China Hospital, Sichuan University

Chengdu, China

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

The First Affiliated Hospital of Fujian Medical University

Fuzhou, China

Dermatology Hospital of Southern Medical University

Guangzhou, China

Guangdong Provincial People's Hospital

Guangzhou, China

Shandong First Medical University-Affiliated Skin Hospital

Jinan, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Henan Provincial People's Hospital

Zhengzhou, China